EX04-019C-US Page 2 of 13

## AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the Application.

## LISTING OF CLAIMS:

- 1-8. (cancelled)
- 9. (currently amended) A compound according to Formula IV.

$$(R^{1})_{1-4}$$
 $(R^{5})_{n}$ 
 $(R^{5})_{n}$ 
 $(R^{5})_{n}$ 

or a pharmaceutically acceptable salt thereof, wherein

X is selected from -H,  $-OR^6$ ,  $-S(O)_{0-2}R^6$ ,  $-N(R^6)R^7$ ,  $-O-N(R^6)R^7$ ,  $-N(R^6)OR^6$ ,

-N(R<sup>6</sup>)N(R<sup>6</sup>)R<sup>7</sup>, absent, oxo, thiono, and imino, with the proviso that when X is oxo, thiono, or imino, there is only one R<sup>1</sup>;

 $R^1$  and  $R^2$ , at each occurance, are each independently selected from -H, halogen, -CN, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N(R<sup>6</sup>)R<sup>7</sup>, -S(O)<sub>0-2</sub>R<sup>7</sup>, -SO<sub>2</sub>N(R<sup>6</sup>)R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)N(R<sup>6</sup>)R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>7</sup>, -N(R<sup>6</sup>)C(O)R<sup>7</sup>, -N(R<sup>6</sup>)CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>6</sup>, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, absent, and optionally substituted lower heterocyclylalkyl;

optionally, at least one pair of substituents, selected from two of R<sup>1</sup>, one of R<sup>2</sup>, and one each of R<sup>1</sup> and R<sup>2</sup>, together with the corresponding carbon or carbons to which they are attached, form a first ring comprising between three and seven annular atoms, said first ring optionally substituted with between zero and four additional of R<sup>1</sup>, each independently selected as defined above and optionally, two of R<sup>1</sup> when are paired,

EX04-019C-US Page 3 of 13

together with the corresponding atom or atoms of the first ring to which they are attached; to form a second ring comprising between three and seven annular <u>carbon</u> atoms, said second ring optionally substituted with between zero and three of R<sup>1</sup>;

R<sup>3</sup> is selected from -H and optionally substituted lower alkyl;

each of  $R^4$  is independently selected from -H, halogen, -CN, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N(R<sup>6</sup>)R<sup>7</sup>, -S(O)<sub>0-2</sub>R<sup>7</sup>, -SO<sub>2</sub>N(R<sup>6</sup>)R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)N(R<sup>6</sup>)R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>7</sup>, -N(R<sup>6</sup>)C(O)R<sup>7</sup>, -N(R<sup>6</sup>)CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>6</sup>, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;

n is zero to four;

each  $R^5$  is independently selected from -H, halogen, -CN, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -NR<sup>6</sup>R<sup>7</sup>, -S(O)<sub>0.2</sub>R<sup>7</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>7</sup>, -N(R<sup>6</sup>)C(O)R<sup>7</sup>, -N(R<sup>6</sup>)CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>6</sup>, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and

R<sup>6</sup> is -H or optionally substituted lower alkyl;

R<sup>7</sup> is selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and

R<sup>6</sup> and R<sup>7</sup>, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl ring, said optionally substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N, O, S, and P.

- 10. (withdrawn) The compound according to claim 9, wherein X is selected from  $-OR^6$ ,  $-SR^6$ , and  $-N(R^6)R^7$ .
- 11. (withdrawn) The compound according to claim 10, wherein two of R<sup>1</sup>, together with the carbon or carbons to which they are attached, form said second ring.

EX04-019C-US Page 4 of 13

12. (withdrawn) The compound according to claim 11, wherein said second ring is a six-membered aryl, fused with said first ring, said second ring optionally substituted with between zero and three of R<sup>1</sup>.

13. (withdrawn) The compound according to claim 12, of formula V.

$$(R^1)_{0-3}$$
 $(R^4)_{0-3}$ 
 $(R^4)_{0-3}$ 

- 14. (withdrawn) The compound according to claim 13, wherein X is -OR<sup>6</sup>.
- 15. (withdrawn) The compound according to claim 14, wherein R<sup>3</sup> is -H.
- 16. (withdrawn) The compound according to claim 15, wherein X is -OH.
- 17. (withdrawn) The compound according to claim 16, of formula VI.

$$(R^1)_{0-3}$$
 $(R^4)_{0-3}$ 
 $(R^4)_{0-3}$ 

- 18. (withdrawn) The compound according to claim 17, wherein R<sup>1</sup>, R<sup>4</sup>, and R<sup>5</sup> are -H.

  19-29. (cancelled)
- 30. (previously presented) A compound according to Table 3:

Table 3

#	Name	Structure

EX04-019C-US Page 5 of 13

Table 3

#	Name	Structure
1	N-cyclohexyl-2-pyridin-4-ylquinazolin-4- amine	HN N N N N N N N N N N N N N N N N N N
3	N-cyclopentyl-2-pyridin-4-ylquinazolin-4- amine	H Z Z Z Z
4	N-(cyclohexylmethyl)-2-pyridin-4- ylquinazolin-4-amine	
7	N-[(4-fluorophenyl)methyl]-2-pyridin-4- ylquinazolin-4-amine	HN N N N N N N N N N N N N N N N N N N
9	N-(2,3-dihydro-1H-inden-1-yl)-2-pyridin- 4-ylquinazolin-4-amine	HN Z Z
12	2-pyridin-4-yl-N-[(2R)-1,2,3,4- tetrahydronaphthalen-2-yl]quinazolin-4- amine	

Table 3

#	Name	Structure
15	2-pyridin-4-yl-N-[(2S)-1,2,3,4- tetrahydronaphthalen-2-yl]quinazolin-4- amine	
18	(1S,2R)-1-[(2-pyridin-4-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	HO, Z
19	1,1-dimethylethyl 4-[(2-pyridin-4- ylquinazolin-4-yl)amino]piperidine-1- carboxylate	N N O + :
24	3-[(2-pyridin-4-ylquinazolin-4- yl)amino]naphthalen-2-ol	HO Z Z
25	N-{4-[(1-methylethyl)oxy]phenyl}-2- pyridin-4-ylquinazolin-4-amine	

EX04-019C-US Page 7 of 13

Table 3

#	Name	Structure
31	(1S,2R)-1-[(6-chloro-2-pyridin-4- ylquinazolin-4-yl)amino]-2,3-dihydro-1H- inden-2-ol	HO N NH
33	(1S,2R)-1-[(2-pyridin-3-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	HN—N—;
45	(15,2R)-1-[(6-bromo-2-pyridin-4- ylquinazolin-4-yl)amino]-2,3-dihydro-1H- inden-2-ol	HO N NH Br ;
46	(1S,2R)-1-{[6,7-bis(methyloxy)-2- pyridin-4-ylquinazolin-4-yl]amino}-2,3- dihydro-1H-inden-2-ol	N—NH NH

EX04-019C-US Page 8 of 13

Table 3

#	Name	Structure
48	(1S,2R)-1-{[2-pyridin-4-yl-7- (trifluoromethyl)quinazolin-4-yl]amino}- 2,3-dihydro-1H-inden-2-ol	HO  N N NH  F3C ;
49	(1S,2R)-1-({2-[6-(methyloxy)pyridin-3-yl]quinazolin-4-yl}amino)-2,3-dihydro-1H-inden-2-ol	HN—N N—O—;
51	(1S,2R)-1-[(7-methyl-2-pyridin-4- ylquinazolin-4-yl)amino]-2,3-dihydro-1H- inden-2-ol	HN N N
54	(2S)-3-methyl-2-[(2-pyridin-4- ylquinazolin-4-yl)amino]butan-1-ol	N—NH OH
55	(2S)-2-phenyl-2-[(2-pyridin-4- ylquinazolin-4-yl)amino]ethanol	N OH NH

EX04-019C-US Page 9 of 13

Table 3

#	Name	Structure
56	(2R)-2-phenyl-2-[(2-pyridin-4- ylquinazolin-4-yl)amino]ethanol	OH NH
61	(2S)-3-phenyl-2-[(2-pyridin-4- ylquinazolin-4-yl)amino]propan-1-ol	HO NH Z
62	2-[(phenylmethyl)(2-pyridin-4- ylquinazolin-4-yl)amino]ethanol	N—N—N—OH
63	(1S,2R)-1-{[2-(2-aminopyrimidin-4-yl)quinazolin-4-yl]amino}-2,3-dihydro-1H-inden-2-ol	HN—N N=N N=N H <sub>2</sub> N;
66	2-{4-[(2-pyridin-4-ylquinazolin-4- yl)amino]piperazin-1-yl}ethanol	OH N NH N y y y and

EX04-019C-US Page 10 of 13

Table 3

#	Name	Structure
67	N-piperidin-1-yl-2-pyridin-4- ylquinazolin-4-amine	

31. (previously presented) A pharmaceutical composition comprising the compound according to claim 9 and a pharmaceutically acceptable carrier.

32-38. (cancelled)